Phanes Therapeutics' PT217 Receives Fast Track Designation from FDA

Phanes Therapeutics' PT217 Receives Fast Track Designation from FDA

By, Admin 12 April 2024

Overview

Phanes Therapeutics, Inc. (Phanes), a biotechnology company specializing in innovative oncology drug discovery and development, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following platinum chemotherapy with or without a checkpoint inhibitor. PT217 was previously granted orphan drug designation for the treatment of small cell lung cancer by the FDA in 2022.

PT217

  • PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47, and it is being developed for the treatment of patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), and extrapulmonary neuroendocrine carcinomas (EP-NECs).

SCLC

  • SCLC is a highly aggressive form of cancer characterized by high mortality rates and significant morbidities. 
  • Patients diagnosed with ES-SCLC typically have an average survival duration of 2-4 months without treatment, which extends to 7-11 months with treatment.

Words from Phanes Therapeutics

Ming Wang, Founder and CEO of Phanes Therapeutics, expressed optimism about PT217's potential, stating, ""PT217 has the potential to be a transformative treatment option for patients with SCLC, LCNEC, and EP-NECs in various settings."" Wang also highlighted Phanes Therapeutics' recent achievement of securing two Fast Track designations, with PT886 receiving similar recognition last month for the treatment of metastatic claudin 18.2-positive pancreatic adenocarcinoma. Both assets are from Phanes' optimized anti-CD47 bispecific antibody franchise and are currently in clinical studies. Wang emphasized the belief in the potential of the optimized anti-CD47 bispecific antibody approach to unlock the full potential of the innate immunity in targeting solid tumors.

SKYBRIDGE Study

The multi-center Phase I clinical trial of PT217 (NCT05652686), known as the SKYBRIDGE study, is currently evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PT217 in patients with advanced or refractory cancers expressing DLL3.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!